◈ PREVIEW jump to any piece · sample data on the report · remove this bar before launch
COG·IGNITION
SYSTEMS READOUT · v4

Ignite your systems.

Your body runs on four interlocking systems — cognitive, endocrine, immune, and cardiovascular. Cog-Ignition grades all four from how you actually live, then hands you the highest-leverage moves to bring them into sync.

What this is

Cog-Ignition is an information model, not a medical test. You describe how you actually live — what you consume, how you sleep and move, what you're exposed to, how you recover — and the system maps those consumption and behavior patterns onto the four physiological systems they influence.

Every answer carries a research-weighted value. Those weights come from a graded ledger that separates what's well established from what's emerging or contested — and it shows you which is which rather than flattening them together. Settled findings drive your scores; promising-but-unproven material is labeled and kept in view instead of being hidden or oversold. That combination is the point: a bigger, honest picture, so you can hold both the mainstream evidence and the edges of it and decide for yourself.

That's what health autonomy actually requires — not trusting us, and not distrusting everyone. Seeing the grade behind every claim, following the source, and reaching your own conclusion.

◈
No registrationNo account, email, or password. Nothing to sign up for.
◆
Real-time scoringYour readout builds live as you answer.
◇
Nothing leaves your deviceEvery calculation runs in your browser. Your answers are never transmitted or stored.
◎
Evidence-gradedEvery claim carries an A–D grade and a source you can check.
The four systems

One wheel, four readouts.

Modern medicine tends to treat the body in isolated parts. Cog-Ignition reads it as one connected system — because your nervous and endocrine systems are literally wired together, and what moves one moves the rest.

The living system

Four systems, one body.

Tap a system to light it up — and see how it wires into the others. Nothing in your body works alone.

Systems thinking

Hover a marker for a quick read · click it for the full explanation

The history

How healing got narrowed to one lineage.

By the early twentieth century, American medical education was already changing. Medical associations, state licensing boards, and universities were raising entrance requirements, lengthening curricula, and pressing schools to provide laboratories and supervised clinical training. The Carnegie Foundation commissioned educator Abraham Flexner to survey 155 medical schools in the United States and Canada. His 1910 report promoted a four-year, university-based model that joined laboratory science to clinical instruction in a teaching hospital.

That model made medical education more rigorous and consistent, but it also accelerated a major consolidation. Schools without substantial laboratories, hospital access, full-time faculty, or stable financing were especially vulnerable. Many proprietary, homeopathic, eclectic, naturopathic, and physiomedical institutions changed their curricula, merged, or closed as accreditation, licensing, and philanthropic funding converged around the same biomedical standard. Flexner did not create that movement alone; his report codified and hastened changes already underway.

The result was not simply that "science won" and everything outside it failed. Institutional survival and therapeutic validity are different questions. Some displaced practices lacked evidence or adequate training; others lost the recognized schools, hospitals, and financing through which they might have been tested and improved. The durable lesson is that standards can protect patients while also determining which kinds of knowledge receive credentials, research money, reimbursement, and a place inside the mainstream.

That same distinction matters in the present. Researchers use disease mongering for widening the boundaries of treatable illness in ways that enlarge markets. Overdiagnosis is narrower: identifying a genuine condition that would never have caused symptoms or harm. Expanded recognition can help people whose problems were once overlooked; the concern begins when definitions, screening thresholds, marketing, or treatment recommendations move faster than evidence that intervention will improve a person's life.

No coordinated conspiracy is required for ordinary incentives to shape a system. U.S. prescription-drug advertising to consumers is lawful and FDA-regulated. Fee-for-service payment can reward the volume of tests and procedures rather than their value, while concentrated manufacturers, insurers, and pharmacy-benefit managers influence what is promoted, covered, and affordable. Documented misconduct such as Purdue Pharma's opioid marketing shows how those pressures can cross legal and ethical lines—but it does not mean every diagnosis, medicine, institution, or clinician is acting in bad faith.

COVID-19 and the injury record. Vaccines were used to reduce severe illness, and safety monitoring also established rare but real adverse effects. Evidence reviews support a causal link between mRNA vaccines and myocarditis, occurring most often in adolescent and young adult males soon after a dose; anaphylaxis is another rare serious reaction. The no-longer-used Janssen vaccine was associated with thrombosis with thrombocytopenia syndrome and Guillain–Barré syndrome. People who experience a vaccine injury deserve care, transparent study, and a workable compensation process. But a report submitted after vaccination is a safety signal, not proof by itself. A trustworthy account distinguishes confirmed causation, plausible signals, unresolved claims, background rates, and risks from infection as well as vaccination.

Cholesterol is not simply a villain. It is essential to cell membranes, steroid hormones, bile acids, and the myelin that insulates nerve fibers. Yet cholesterol in the central nervous system is largely synthesized and regulated behind the blood–brain barrier, while LDL measured in blood belongs mainly to peripheral circulation; one pool is not simply drained from the other. Statins reduce heart attack and ischemic stroke risk for many higher-risk patients, but they are neither universally necessary nor free of harms. Some people experience muscle symptoms; serious muscle injury is rare, diabetes risk rises modestly in susceptible patients, and FDA labeling notes rare postmarketing cognitive complaints generally described as nonserious and reversible. Randomized trials and systematic reviews do not support the claim that statins inevitably cause cognitive decline or neurodegeneration. The useful question is not "cholesterol: good or bad?" but who is likely to benefit, by how much, at what dose, with what interactions, symptoms, alternatives, and monitoring.

Medical freedom grows through better information. A useful research ledger separates raw reports from verified diagnoses, sequence from causation, relative risk from absolute risk, population averages from individual response, and known harms from open questions. Power deserves scrutiny, but "they" is not an evidence category: name the actor, mechanism, funding, conflict, source, and uncertainty. That is how education helps a person become a smarter health consumer without turning skepticism into automatic acceptance or automatic refusal.

This is not an argument against medicine—or against questioning it. Emergency care, surgery, antibiotics, imaging, vaccination, and evidence-based treatment are among the finest things our species has built. It is an argument for plurality, informed consent, and the right to inspect the claim: judge each intervention by its evidence, likely benefit, possible harm, conflicts, and alternatives. Traditional and complementary practices deserve honest testing rather than automatic romanticizing or automatic exclusion. Some will hold up; some will not. Cog-Ignition makes the grade and source visible so you can tell the difference. This exhibit is educational and is not individualized medical advice; do not begin, stop, or change a treatment without discussing your circumstances with a qualified clinician.

Source trail: Carnegie · Flexner Report · BMJ · disease mongering · NCI · overdiagnosis · FDA · drug promotion · CMS · value-based care · FTC · PBM consolidation · DOJ · Purdue Pharma · National Academies · COVID vaccine evidence · CDC · COVID vaccine safety · CDC · reading VAERS reports · PubMed · brain cholesterol · FDA · atorvastatin label · Systematic review · cognition · USPSTF · statin decisions

The mission

Your body, back in your own hands.

For most of human history, health knowledge belonged to the people living inside the body. It moved through families and traditions as food, rest, movement, seasons, sunlight, and plants — observed over centuries, refined by whoever was still standing. Somewhere in the last hundred years that knowledge got centralized: handed to institutions, encoded in a language nobody taught you, and returned in fifteen-minute appointments.

Modern medicine earned its authority honestly. At rescue it is extraordinary — trauma, infection, acute crisis, surgery. Nothing in history compares, and if you are in danger, that is exactly where you should be. But rescue is not the same as flourishing. The system built to save your life was never built to tell you why you're exhausted at thirty-four, why your sleep decayed, or why inflammation crept in while every test came back "normal."

That gap is where Cog-Ignition lives — not as opposition to medicine, but as leverage against ignorance. The counterforce isn't a rival doctrine. It's information placed back in your hands: what your daily inputs are actually doing across your systems, which practices hold up under evidence, who profits from your confusion, and where the science is genuinely unsettled.

We take the older traditions seriously enough to test them rather than romanticize them. Where they hold up — botanicals and adaptogens, fasting, fermented foods, sunlight, movement, breath, touch, community — we show you the evidence and the grade behind it. Where the evidence is thin or absent, we say that just as plainly. That honesty is the entire point: an informed person is harder to sell to, harder to frighten, and harder to make dependent. Both the supplement aisle and the outrage feed rely on you not checking.

You are the instrument and the operator. This is your readout.

The idea

Systems thinking for your own biology.

Every system — mechanical, informational, biological — runs on the same fundamentals: structure, feedback, adaptation. The human body is no exception. When its core systems are in balance, capacity feels almost limitless. When they drift, dysfunction spreads like a cascading failure.

The shift already underway in health is from managing disease to preventing it — from reacting to symptoms toward understanding the inputs that shape them. Cog-Ignition is built for that shift: a clear, structured read on how your daily choices land across your physiology, so you can act on causes instead of chasing effects.

Knowledge here isn't abstract. It's the difference between guessing and steering.

The population readout / Conditions & prescriptions

Living with illness.
Living with medication.

How widespread are chronic conditions—and how much of everyday life now involves a prescription? Two national surveys offer complementary views of that landscape.

Adults age 18+ · 2023 · BRFSS
76.4%

At least one chronic condition

About 194 million adults in the study's covered population. 51.4% had two or more of the 12 selected conditions.

All ages · Aug 2021–Aug 2023 · NHANES
53.1%

At least one prescription medication

Reported use in the past 30 days. 27.9% used three or more; 14.7% used five or more.

Different denominators: the chronic-condition estimate covers adults; the prescription estimate includes children. These are separate surveys and cannot tell us what proportion of people with chronic conditions take medication, or how many people belong to both groups.

01 / Chronic-condition prevalence

A growing burden

U.S. adults age 18+ · percent · not age-adjusted

1+ conditions2+ conditions
Percent of population over time. Full estimates in the data table below.02550751001+ conditions · 2013: 72.3%1+ conditions · 2015: 71.7%1+ conditions · 2017: 72.0%1+ conditions · 2019: 73.0%1+ conditions · 2021: 75.1%1+ conditions · 2023: 76.4%2+ conditions · 2013: 47.3%2+ conditions · 2015: 46.5%2+ conditions · 2017: 47.1%2+ conditions · 2019: 47.9%2+ conditions · 2021: 49.6%2+ conditions · 2023: 51.4%201320182023

One or more selected conditions: 72.3% in 2013 → 76.4% in 2023. Two or more: 47.3% → 51.4%. A broader condition list produces a higher estimate than a narrower list.

Data & source
Adults age 18+; selected conditions; BRFSS
Period1+ conditions2+ conditions
201372.3%47.3%
201571.7%46.5%
201772.0%47.1%
201973.0%47.9%
202175.1%49.6%
202376.4%51.4%

CDC / Preventing Chronic Disease · figure data ↗

02 / Prescription use

The medication footprint

U.S. population, all ages · past 30 days · not age-adjusted

1+ medications3+ medications5+ medications
Percent of population over time. Full estimates in the data table below.02550751001+ medications · 1988–1994: 37.8%1+ medications · 2001–2004: 46.5%1+ medications · 2005–2008: 47.9%1+ medications · 2009–2012: 48.7%1+ medications · 2013–2016: 48.4%1+ medications · 2017–March 2020: 49.9%1+ medications · August 2021–August 2023: 53.1%3+ medications · 1988–1994: 11.0%3+ medications · 2001–2004: 19.9%3+ medications · 2005–2008: 21.4%3+ medications · 2009–2012: 21.8%3+ medications · 2013–2016: 24.0%3+ medications · 2017–March 2020: 24.7%3+ medications · August 2021–August 2023: 27.9%5+ medications · 1988–1994: 3.6%5+ medications · 2001–2004: 9.0%5+ medications · 2005–2008: 10.5%5+ medications · 2009–2012: 10.7%5+ medications · 2013–2016: 12.6%5+ medications · 2017–March 2020: 13.5%5+ medications · August 2021–August 2023: 14.7%199120062022

Published survey periods from 1988–1994 through August 2021–August 2023. Thresholds overlap: people using five medications also count in the one-or-more and three-or-more groups.

Data & source
All ages; prescription use in past 30 days; NHANES
Period1+ medications3+ medications5+ medications
1988–199437.8%11.0%3.6%
2001–200446.5%19.9%9.0%
2005–200847.9%21.4%10.5%
2009–201248.7%21.8%10.7%
2013–201648.4%24.0%12.6%
2017–March 202049.9%24.7%13.5%
August 2021–August 202353.1%27.9%14.7%

CDC / NCHS · prescription medication dataset ↗

A closer age comparison / Adults 65+

Both are common in later life.

The same age threshold gives a closer comparison, but these still measure different things in different samples.

1+ selected chronic conditions · 202393.0%
1+ prescription medications · 2021–202389.2%
0%50%100%
Which medications?

Common drug categories

Top five categories in each age group, from a 2015–2016 U.S. NHANES snapshot published in 2019. Percentages refer to all adults in that age group who used the category in the past 30 days—not the share of prescriptions or drug users. People can appear in several categories; the bars do not add to 100%.

Historical snapshot / 2015–2016

Ages 40–59

Percent using each category · past 30 days

Antidepressants15.4%
Lipid-lowering drugs13.9%
ACE inhibitors11.4%
Prescription analgesics11.1%
Antidiabetic agents8.8%
0%25%50%

NCHS Data Brief 347 · Figure 4 ↗

Historical snapshot / 2015–2016

Ages 60–79

Percent using each category · past 30 days

Lipid-lowering drugs45.0%
Antidiabetic agents23.6%
Beta blockers22.3%
ACE inhibitors21.3%
Proton pump inhibitors16.9%
0%25%50%

NCHS Data Brief 347 · Figure 4 ↗

Lipid-lowering drugs treat cholesterol; ACE inhibitors and beta blockers are used for blood pressure and some heart conditions; antidiabetic agents manage diabetes; analgesics treat pain; proton pump inhibitors reduce stomach acid. Categories can serve more than one purpose. This historical ranking does not represent today's prescribing mix.

Where did "nearly 70%" come from?

A widely circulated 2013 Mayo Clinic report drew on 2009 records from Olmsted County, Minnesota: 68.1% received a prescription from at least one drug group during the year. It measured prescriptions issued over 12 months, not nationwide use in a typical month or confirmed long-term treatment. Read the original study ↗

A separate CDC report published in 2019 found 69.0% of U.S. adults ages 40–79 used at least one prescription in the past 30 days in 2015–2016. That age range excludes children, younger adults and people age 80 and older. Read the CDC report ↗

Definitions, uncertainty & the relationship between the numbers

The chronic-condition study counts arthritis, cancer excluding skin cancer, chronic kidney disease, COPD, depression, diabetes excluding gestational diabetes, heart disease, high blood pressure, high cholesterol, stroke, current asthma and obesity. Most are self-reported prior professional diagnoses; obesity is calculated from self-reported height and weight. "Ever diagnosed" does not necessarily mean currently symptomatic. Kentucky and Pennsylvania were absent from the 2023 BRFSS public-use data; other years also had state omissions. The authors' population count reflects covered areas, not a full census.

NHANES measures reported prescription use during the preceding 30 days, excluding prescription dietary supplements. These charts use crude percentages, not age-adjusted estimates; population aging can influence the trends. The survey restarted with a new design in 2021. Points represent published survey periods, positioned at midpoints, and lines only connect estimates. Missing periods are not reconstructed. Survey estimates have sampling uncertainty; confidence intervals and methods are available in the sources.

Chronic conditions can lead to medication use, but medicines are also prescribed for prevention, short-term illness and other purposes. A medication count does not establish dependence, inappropriate prescribing, benefit or harm. Measuring the overlap—or whether treatment improved health—requires linked individual-level evidence. These population totals do not establish causation.

Sources checked October 13, 2026: chronic-condition study · prescription-use data and confidence intervals · historical drug categories.

The economics of care · 2019–2025

When illness becomes a market.

Who pays—and who benefits? Put the business of medicine beside the health trends above. These four companies show the scale of pharmaceutical revenue, the extraordinary COVID-era surge in some businesses, and what happened after demand fell.

$56.7BPfizer's COVID-product revenue, 2022
Comirnaty + Paxlovid. Sales, before costs.
$31.4BPfizer's total net income, 2022
Company-wide GAAP earnings after expenses and taxes.
$12.2BModerna's total net income, 2021
A pandemic-era profit peak; losses followed in 2023–2025.

Revenue is money recognized from business activity. Net income is the accounting profit or loss after expenses, other gains or losses, and taxes. Neither is the same as cash paid to shareholders.

Annual figures · nominal U.S. dollars, billions · worldwide business · same scale across all four companies for each measure. Values are as originally reported each year; portfolio and accounting changes are explained below.

Pfizer

Revenue · USD billions
Pfizer: revenue, 2019–2025, billions of U.S. dollars02550751002019: $51.750B51.8192020: $41.908B41.9202021: $81.288B81.3212022: $100.330B100.3222023: $58.496B58.5232024: $63.627B63.6242025: $62.579B62.625
GAAP net income / loss · USD billions
Pfizer: GAAP net income or loss, 2019–2025, billions of U.S. dollars-100102030402019: $16.273B16.3192020: $9.616B9.6202021: $21.979B22.0212022: $31.372B31.4222023: $2.119B2.1232024: $8.031B8.0242025: $7.771B7.825

The 2022 peak includes COVID vaccines and treatments. The Upjohn separation changes the revenue base in 2020; royalty income moves into revenue in 2024. Earlier earnings also include discontinued businesses and disposal gains.

Annual values & original filings
Pfizer · USD billions, rounded to three decimals. Net income includes discontinued operations.
Fiscal yearRevenueNet incomeSource
201951.75016.27310-K
202041.9089.61610-K
202181.28821.97910-K
2022100.33031.37210-K
202358.4962.11910-K
202463.6278.03110-K
202562.5797.77110-K

Johnson & Johnson

Revenue · USD billions
Johnson & Johnson: revenue, 2019–2025, billions of U.S. dollars02550751002019: $82.059B82.1192020: $82.584B82.6202021: $93.775B93.8212022: $94.943B94.9222023: $85.159B85.2232024: $88.821B88.8242025: $94.193B94.225
GAAP net income / loss · USD billions
Johnson & Johnson: GAAP net income or loss, 2019–2025, billions of U.S. dollars-100102030402019: $15.119B15.1192020: $14.714B14.7202021: $20.878B20.9212022: $17.941B17.9222023: $35.153B35.2232024: $14.066B14.1242025: $26.804B26.825

Includes medicines and medical technology. Kenvue leaves revenue in 2023. That year's $35.2B net income includes a $21.0B Kenvue disposal gain; continuing-operations earnings were $13.3B. A roughly $7B pre-tax talc-reserve reversal lifted 2025 earnings.

Annual values & original filings
Johnson & Johnson · USD billions, rounded to three decimals. Net income includes discontinued operations.
Fiscal yearRevenueNet incomeSource
201982.05915.11910-K
202082.58414.71410-K
202193.77520.87810-K
202294.94317.94110-K
202385.15935.15310-K
202488.82114.06610-K
202594.19326.80410-K

Moderna

Revenue · USD billions
Moderna: revenue, 2019–2025, billions of U.S. dollars02550751002019: $0.060B0.06192020: $0.803B0.8202021: $18.471B18.5212022: $19.263B19.3222023: $6.848B6.8232024: $3.236B3.2242025: $1.944B1.925
GAAP net income / loss · USD billions
Moderna: GAAP net income or loss, 2019–2025, billions of U.S. dollars-100102030402019: −$0.514B−0.5192020: −$0.747B−0.7202021: $12.202B12.2212022: $8.362B8.4222023: −$4.714B−4.7232024: −$3.561B−3.6242025: −$2.822B−2.825

COVID vaccine sales transformed a small pre-commercial business. Large profits in 2021–2022 were followed by losses in 2023–2025 as sales fell; inventory charges and continued research spending also affected earnings.

Annual values & original filings
Moderna · USD billions, rounded to three decimals. Net income includes discontinued operations.
Fiscal yearRevenueNet incomeSource
20190.060-0.51410-K
20200.803-0.74710-K
202118.47112.20210-K
202219.2638.36210-K
20236.848-4.71410-K
20243.236-3.56110-K
20251.944-2.82210-K

Merck & Co. / MSD

Revenue · USD billions
Merck & Co. / MSD: revenue, 2019–2025, billions of U.S. dollars02550751002019: $46.840B46.8192020: $47.994B48.0202021: $48.704B48.7212022: $59.283B59.3222023: $60.115B60.1232024: $64.168B64.2242025: $65.011B65.025
GAAP net income / loss · USD billions
Merck & Co. / MSD: GAAP net income or loss, 2019–2025, billions of U.S. dollars-100102030402019: $9.843B9.8192020: $7.067B7.1202021: $13.049B13.0212022: $14.519B14.5222023: $0.365B0.4232024: $17.117B17.1242025: $18.254B18.325

The U.S. company, including animal health. Organon leaves the revenue base in 2021. Major acquisition and collaboration charges depressed 2023 earnings, including $10.2B for Prometheus and $5.5B for the Daiichi Sankyo collaboration.

Annual values & original filings
Merck & Co. / MSD · USD billions, rounded to three decimals. Net income includes discontinued operations.
Fiscal yearRevenueNet incomeSource
201946.8409.84310-K
202047.9947.06710-K
202148.70413.04910-K
202259.28314.51910-K
202360.1150.36510-K
202464.16817.11710-K
202565.01118.25410-K
Zoom in · fiscal 2022

The COVID products behind the surge.

Selected worldwide product revenue, USD billions. Bars share a zero baseline and a $40B scale. These figures are revenue, not product profit.

ComirnatyPfizer
$37.806B
PaxlovidPfizer
$18.933B
$18.435B
LagevrioMerck & Co.
$5.684B
COVID-19 vaccineJohnson & Johnson
$2.179B

The peak was not permanent: Pfizer's combined Comirnaty and Paxlovid revenue fell from $56.739B in 2022 to $6.729B in 2025—about 88% lower. 2025 product sales.

Pfizer reports Comirnaty through direct and alliance revenue; its BioNTech partnership shares economics. Merck's Lagevrio partnership also shares economics with Ridgeback. These are the named companies' recognized revenues, not a sum of all manufacturers' profits. Later returns and contract adjustments can affect reported sales.

Public money. Private earnings. Public accountability.

By December 31, 2020, HHS and the Department of Defense had obligated approximately $13B to six vaccine companies for doses and associated development or manufacturing activities, according to GAO. That is an early U.S. funding snapshot—not total pandemic spending, cash already paid, or a measure of profit.

These records support scrutiny of prices, public funding, access and how the gains were distributed. They do not, by themselves, measure money lost by ordinary households or show whether a treatment helped or harmed patients. To trace a wealth transfer, follow procurement contracts, taxes and insurance payments, costs, dividends, buybacks and ownership alongside health outcomes.

The question for the exhibit

When the public helps finance medical innovation, what should it receive in return—and how should affordability, risk and financial reward be shared?

How to read these charts · accounting changes & sources

Data checked October 13, 2026. Each point comes from the first Form 10-K for that fiscal year, accessed through the SEC's Company Facts data. This preserves what each company reported at the time, rather than mixing original and subsequently restated values. Tables link to those filings. Fiscal year labels are used, including Johnson & Johnson's calendar-adjacent year end. 2025 is the latest complete fiscal year shown; no 2026 forecasts are included.

Revenue covers the whole reported company, not just pharmaceuticals or COVID products. Net income is GAAP earnings attributable to the parent or common shareholders, including discontinued operations; it is not adjusted earnings, operating cash flow or product-level profit. Revenue and earnings can have different scopes after disposals. Do not interpret their ratio as a comparable operating margin across these years.

  • Pfizer: the 2020 Upjohn separation, other portfolio changes and the 2024 royalty-revenue reclassification affect comparisons. The original 2022 revenue figure is $100.330B; later reports restate it to $101.175B. 2024 accounting presentation.
  • Johnson & Johnson: the 2023 Kenvue disposal gain is included in total net income while the consumer business is excluded from that year's continuing revenue. 2025 includes the talc-reserve reversal. Financial statements and litigation notes.
  • Merck: the 2021 Organon separation changes the revenue base. The 2023 earnings decline includes substantial business-development expenses. 2023 annual filing.
  • Moderna: total revenue includes grants and collaborations; COVID-product revenue excludes them. Later product sales also include non-COVID products. 2025 annual filing.

Selection: two large diversified companies requested for this exhibit, Pfizer and Johnson & Johnson, plus Moderna and Merck to compare vaccine and antiviral businesses. This is not a ranking or a representative sample of the industry. Figures are worldwide and unadjusted for inflation. The U.S. health charts above describe different populations and cannot establish a causal relationship with these financial results.

Featured sub-exhibit · Project archive

Ease Medical Center

A preserved vision for regenerative, integrative care—revisited as a project archive and a proposition for what might still be built.

Ease Medical Center regenerative and integrative medical campus exhibit

More than a decade ago, Buff Nemeth brought me the Ease Medical Center project, a startup she founded. My role was to help communicate and promote her startup through graphics, visuals, PowerPoint presentations, and supporting materials. This exhibit preserves that body of work and places it in the wider Cog-Ignition inquiry.

The need behind the idea remains urgent. I am presenting it now in dedication to the project—and in the hope that something like it can one day manifest.

Regenerative medicine · Integrative care · Systems design
Enter the Ease Medical Center exhibit →
Begin

Start your ignition sequence.

Read me first. Cog-Ignition is an educational self-assessment — not a medical diagnosis, lab test, or treatment plan. It maps well-established lifestyle factors to how your body tends to function, and suggests widely-available nutraceuticals for context only. Supplements can interact with medications and conditions: talk to a clinician or pharmacist before starting anything, especially if you're pregnant, nursing, on medication, or managing a health condition.